Dogged by ac­cu­sa­tions of shady sales prac­tices, Alex­ion finds it­self un­der in­ves­ti­ga­tion by HHS -- Bloomberg

Shares of Alex­ion Phar­ma­ceu­ti­cals took a hit on Thurs­day af­ter­noon af­ter Bloomberg re­port­ed that the OIG’s of­fice in Health and Hu­man Ser­vices has opened an in­ves­ti­ga­tion in­to the com­pa­ny. The state­ment from the fed­er­al agency came in re­sponse to a Free­dom of In­for­ma­tion Act query and didn’t de­tail the rea­sons for the probe.

Alex­ion’s shares $ALXN tum­bled 4% on the news.

Alex­ion, though, has been un­der a cloud since its CEO and CFO got the boot late last year fol­low­ing in­ter­nal al­le­ga­tions re­gard­ing the com­pa­ny’s sales prac­tices. The com­pa­ny was ac­cused of pres­sur­ing reps to push ex­pe­dit­ed Soliris sales. And the SEC and De­part­ment of Jus­tice have got­ten in­to the act with their own in­ves­ti­ga­tions of the com­pa­ny un­der the For­eign Cor­rupt Prac­tices Act.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER